Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes

Figure 1 Flow diagram showing patient screening, enrollment, exclusions, and study completion. A total of 84 patients were assessed for eligibility, 79 were enrolled, and 67 completed the study. SGLT2i: Sodium-glucose cotransporter 2 inhibitor.

Figure 2 Change in liver stiffness in a single patient following 6 months of sodium-glucose cotransporter 2 inhibitor therapy. A: Baseline liver stiffness corresponding to fibrosis stage F2 (8.31 kPa); B: Liver stiffness after 6 months of sodium-glucose cotransporter 2 inhibitor therapy corresponding to fibrosis stage F0/F1 (6.94 kPa).